Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

Baqsimi is a dry nasal spray to treat low blood sugar in people with diabetes aged four years and above. The acquisition deal provided Amphastar with a commercial-stage product with growing sales ...

Boehringer Ingelheim, GSK, Novartis, Teva, and Covis Pharma have been taken to task for asthma and COPD inhalers, while Amphastar Pharma has been warned over its Baqsimi glucagon nasal spray ...

Amphastar's Q2 2024 revenue grew 25% year-over-year to $182.4 million, primarily driven by BAQSIMI and Primatene ... Amphastar pointed to REXTOVY (nasal naloxone for suspected opioid overdose ...